Show simple item record

dc.contributor.authorO'NEILL, DESMONDen
dc.contributor.authorMCCABE, DOMINICKen
dc.contributor.authorCOUGHLAN, TARAen
dc.date.accessioned2016-01-11T15:00:19Z
dc.date.available2016-01-11T15:00:19Z
dc.date.issued2014en
dc.date.submitted2014en
dc.identifier.citationTobin WO, Kinsella JA, Kavanagh GF, O'Donnell JS, McGrath RT, Coughlan T, Collins DR, O'Neill D, Egan B, Tierney S, Feeley TM, Murphy RP, McCabe DJ, Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke., Journal of Neurology, 2014en
dc.identifier.issn0340-5354en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/75566
dc.descriptionPUBLISHEDen
dc.description.abstractThe impact of commencing or changing antiplatelet therapy on von Willebrand factor antigen (VWF:Ag) and von Willebrand factor propeptide (VWF:Ag II) levels has not been comprehensively assessed following TIA or ischaemic stroke. In this pilot, longitudinal, observational analytical study, VWF:Ag and VWF:Ag II levels were simultaneously quantified in platelet poor plasma by ELISA in patients within 4 weeks of TIA or ischaemic stroke (baseline), and then 14 days (14d) and >90 days (90d) after altering antiplatelet therapy. Ninety-one patients were recruited. Eighteen were initially assessed on no antiplatelet therapy, and then after 14d (N = 17) and 90d (N = 8) on aspirin monotherapy; 21 patients were assessed on aspirin and after 14d and 90d on clopidogrel; 52 were assessed on aspirin monotherapy, and after 14d and 90d on aspirin and dipyridamole combination therapy. VWF:Ag, VWF:Ag II levels and VWF:Ag/VWF:Ag II ratio were unchanged at 14d and 90d in the overall study population (p ≥ 0.1). VWF:Ag and VWF:Ag II levels remained stable at 14d and 90d after commencing aspirin (p ≥ 0.054), and after changing from aspirin to clopidogrel (p ≥ 0.2). Following the addition of dipyridamole MR to aspirin, there was a significant reduction in VWF:Ag levels at 14d (p = 0.03) and 90d (p = 0.005), but not in VWF:Ag II levels (p ≥ 0.3). The addition of dipyridamole to aspirin led to a persistent reduction in VWF:Ag but not in VWF:Ag II levels, suggesting that dipyridamole may inhibit release of platelet-derived VWF:Ag following TIA or ischaemic stroke.en
dc.language.isoenen
dc.relation.ispartofseriesJournal of Neurologyen
dc.rightsYen
dc.subjectStrokeen
dc.titleLongitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.en
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/doneillen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/mccabedoen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/coughlten
dc.identifier.rssinternalid93872en
dc.identifier.doihttp://dx.doi.org/10.1007/s00415-014-7362-3en
dc.rights.ecaccessrightsopenAccess
dc.subject.TCDThemeAgeingen
dc.subject.TCDThemeNeuroscienceen
dc.subject.TCDTagAge related diseasesen
dc.identifier.orcid_id0000-0002-5542-9897en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record